Results Provide New Evidence of the Recommended Formula
Determined in the AREDS2 Study
LAVAL, Quebec, May 11, 2021 /CNW/ -- Bausch + Lomb, a
leading global eye health business of Bausch Health Companies Inc.
(NYSE/TSX: BHC) ("Bausch Health"), today announced new data from
the National Eye Institute (NEI) 10-Year Follow-on Study
Results of the Age-Related Eye Disease Study 2 (AREDS2), which
reaffirms the clinical outcomes of the AREDS2 study. Based on
this data, the NEI continues to recommend a specific nutrient
formula to help reduce the risk of progression in patients with
moderate to advanced Age-Related Macular Degeneration
(AMD).1 That formula is currently found in
Bausch + Lomb PreserVision® AREDS 2 Formula eye
vitamins, which was provided to participants in the last five years
of the follow-on study. The study results were presented at the
Association for Research in Vision and Ophthalmology annual meeting
on May 7, 2021.
"These new, longer-term results from the NEI build on the findings
of previous AREDS studies, which show that a precise mix and dosage
of specific vitamins, minerals and antioxidants can help reduce the
risk of progression in people who have moderate to advanced AMD,"
said Rishi P. Singh, M.D., professor
of ophthalmology, Lerner College of Medicine, and staff surgeon at
the Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio. "These findings further
clarify the importance of an AREDS2 supplement as part of a
patient's plan, and the need for eye care professionals to provide
a specific recommendation for this formulation in appropriate
patients."
The NEI's 10-Year Follow-on Study of AREDS2 analysis included 3,887
people (6,360 study eyes) with intermediate to advanced AMD over a
10 year period. The study further validated the original findings
about the AREDS2 formulation with 80mg of zinc and provided support
for the continued benefit of lutein and zeaxanthin, which were
shown to have an incremental beneficial effect as compared to
beta-carotene.1
"For more than 20 years, Bausch + Lomb has been collaborating
with researchers at the NEI to help eye care professionals and the
11 million Americans who are impacted by moderate to advanced AMD,"
said Joe Gordon, U.S. president,
Bausch + Lomb. "Since 2001, we have offered a portfolio of eye
vitamins based on the most current, available science, and this
data further supports the current formulation in our
PreserVision® AREDS 2 Formula eye vitamins."
For more information on PreserVision® AREDS
2 formula eye vitamins, visit www.preservision.com.
About the AREDS, AREDS2 and 10-Year Follow-on AREDS2 Study
Results
The AREDS and AREDS2 studies are landmark clinical
studies conducted over 20 years by the NEI. The AREDS study in 2001
demonstrated that taking a specific combination of antioxidants and
zinc could help reduce the risk of progression of AMD in those with
moderate to advanced AMD. In 2012, the NEI completed the AREDS2
study, which tested several changes to the formulation, such as
adding omega-3 fatty acids, substituting lutein and zeaxanthin for
beta-carotene, and/or reducing zinc. The current AREDS2 nutrient
formula recommended by the NEI is the result of this study. The NEI
10-Year Follow-on Study results evaluated the long-term results of
participants who were involved in the AREDS2 study.
About Age-related Macular Degeneration
AMD is a
progressive eye condition that impacts central vision and is a
leading cause of vision loss in adults aged 50 and
older.2 Early-stage AMD often does not present any
symptoms or changes in vision, as symptoms usually appear gradually
over time.2 This progressive condition can impact
one or both eyes, causing people to have difficulty with daily
activities like driving, reading or recognizing the faces of loved
ones.2
About PreserVision® AREDS 2 Formula Eye
Vitamins
PreserVision AREDS 2 Formula eye vitamins, the
most studied eye vitamin brand3, contain the exact
NEI-recommended formula based on the AREDS2 study. The daily dose
(two capsules) of PreserVision AREDS 2 vitamins provides the
exact same levels of all six clinically proven nutrients as the NEI
supported formula: vitamin C (500mg), vitamin E (400 IU/180mg),
lutein (10mg), zeaxanthin (2mg), zinc (80mg zinc oxide), and copper
(2mg cupric oxide).
About Bausch + Lomb
Bausch + Lomb, a leading global
eye health business of Bausch Health Companies Inc., is solely
focused on helping people see. Its core businesses include
over-the-counter products, dietary supplements, eye care products,
ophthalmic pharmaceuticals, contact lenses, lens care products,
ophthalmic surgical devices and instruments. Bausch + Lomb
develops, manufactures and markets one of the most comprehensive
product portfolios in the industry, which is available in
approximately 100 countries. For more information,
visit www.bausch.com.
About Bausch Health
Bausch Health Companies Inc.
(NYSE/TSX: BHC) is a global company whose mission is to improve
people's lives with our health care products. We develop,
manufacture and market a range of pharmaceutical, medical device
and over-the-counter products, primarily in the therapeutic areas
of eye health, gastroenterology and dermatology. We are delivering
on our commitments as we build an innovative company dedicated to
advancing global health. More information can be found at
www.bauschhealth.com.
Forward-looking Statements
This news release may
contain forward-looking statements, which may generally be
identified by the use of the words "anticipates," "expects,"
"intends," "plans," "should," "could," "would," "may," "believes,"
"estimates," "potential," "target," or "continue" and variations or
similar expressions. These statements are based upon the current
expectations and beliefs of management and are subject to certain
risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
These risks and uncertainties include, but are not limited to, the
risks and uncertainties discussed in Bausch Health's most recent
annual report on Form 10-K and detailed from time to time in Bausch
Health's other filings with the U.S. Securities and Exchange
Commission and the Canadian Securities Administrators, which
factors are incorporated herein by reference. They also include,
but are not limited to, risks and uncertainties caused by or
relating to the evolving COVID-19 pandemic, and the fear of that
pandemic and its potential effects, the severity, duration and
future impact of which are highly uncertain and cannot be
predicted, and which may have a material adverse impact on Bausch
Health, including but not limited to its project development
timelines, and costs (which may increase). Readers are cautioned
not to place undue reliance on any of these forward-looking
statements. These forward-looking statements speak only as of the
date hereof. Bausch Health undertakes no obligation to update any
of these forward-looking statements to reflect events or
circumstances after the date of this news release or to reflect
actual outcomes, unless required by law.
References
- The Results of the 10 Year Follow-on Study of the
Age-Related Eye Disease Study 2 (AREDS2); Emily Y. Chew,
Traci E. Clemons, Tiarnan D. Keenan, Elvira Agron, Claire E.
Malley, Amitha Domalpally.
- National Eye Institute: Age-Related Macular
Degeneration
- Based on the AREDS and AREDS2 studies
PreserVision is a trademark of Bausch & Lomb Incorporated
or its affiliates.
AREDS and AREDS2 are registered trademarks of the United States
Department of Health and Human Services (HHS).
Any other product/brand names and/or logos are trademarks of the
respective owners.
© 2021 Bausch & Lomb Incorporated
or its affiliates.
PV2.0037.USA.20
Investor
Contact:
|
Media
Contact:
|
Arthur
Shannon
|
Lainie
Keller
|
arthur.shannon@bauschhealth.com
|
lainie.keller@bauschhealth.com
|
(514)
856-3855
|
(908)
927-1198
|
(877) 281-6642 (toll
free)
|
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/new-national-eye-institute-data-shows-areds2-nutrient-formula-continues-to-reduce-the-risk-of-moderate-to-advanced-age-related-macular-degeneration-progression-301288304.html
SOURCE Bausch Health Companies Inc.